

Actinogen Medical Ltd

16:30 06 Oct 2015

Actinogen Medical on track with Alzheimer drug trial

Alzheimer's disease drug developer Actinogen Medical (ASX:ACW) is on a path to the second critical phase of its clinical trial with its promising new treatment for patients with alzheimer's dementia.

Its novel drug compound Xanamem targets the enzyme 11beta-HSD1 blocking production of excess cortisol and negative effects of elevated levels.

The trial which is being conducted in Perth saw Xanamem effectively delivered by oral administration to the brain in doses that are predicted to inhibit the 11beta-HSD1 enzyme in the brain in patients.

Cortisol is known as the "stress hormone", and excess cortisol in the brain is associated with memory loss, amyloid plaquing and neural death, the hallmarks of Alzheimer's disease.

With the results, Actinogen Medical will move to a Phase II trial to demonstrate the effectiveness of Xanamem in treating patients suffering from mild Alzheimer's disease.

The second phase of the trial will treat around 200 patients in Australia, the UK and the USA, under a U.S. Food & Drug Administration (FDA) approved Investigational New Drug (IND).

The prize for a successful drug is significant with a multi-billion dollar market potential. The cost of alzheimer's treatment in the US alone was estimated to be US\$250 billion in 2013, with this cost estimated to increase to US\$1 trillion by 2050.

Alzheimer's disease is now the second leading cause of death in Australia.

Actinogen is fully funded for its pivotal Phase II clinical trial.

Positive results from this Phase II trial could see a significant partnering potential given the interest in alzheimers from pharmaceutical companies.

In late September, 24 million shares were traded in the company in one day.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: A\$0.055

Market Cap: A\$34.11M

1 Year Share Price Graph



Share Information

Code: ACW

Listing: ASX

52 week	High	Low
	0.092p	0.04p

Sector: Pharma & Biotech

Website: www.actinogen.com.au

Company Synopsis:

Actinogen Medical Ltd (ASX:ACW) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.